C Anthony Hunt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2094481/publications.pdf

Version: 2024-02-01

		279798	345221
78	1,553	23	36
papers	citations	h-index	g-index
93	93	02	1216
93	93	93	1216
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Contrasting model mechanisms of alanine aminotransferase (ALT) release from damaged and necrotic hepatocytes as an example of general biomarker mechanisms. PLoS Computational Biology, 2020, 16, e1007622.	3.2	17
2	Propagation of Pericentral Necrosis During Acetaminophen-Induced Liver Injury: Evidence for Early Interhepatocyte Communication and Information Exchange. Toxicological Sciences, 2019, 169, 151-166.	3.1	12
3	Establishing model mechanismâ€based causal linkages between APAPâ€induced hepatic necrosis and serum ALT. FASEB Journal, 2019, 33, 506.11.	0.5	О
4	In vitro–in vivo extrapolation of hepatic clearance: using virtual experiments to identify a plausibly influential source of inaccuracies. FASEB Journal, 2019, 33, .	0.5	0
5	A Model Mechanism-Based Explanation of an In Vitro-In Vivo Disconnect for Improving Extrapolation and Translation. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 127-138.	2.5	8
6	The Spectrum of Mechanism-Oriented Models and Methods for Explanations of Biological Phenomena. Processes, 2018, 6, 56.	2.8	19
7	Simulation enabled search for explanatory mechanisms of the fracture healing process. PLoS Computational Biology, 2018, 14, e1005980.	3.2	3
8	A cell-centered, agent-based framework that enables flexible environment granularities. Theoretical Biology and Medical Modelling, 2016, 13, 4.	2.1	7
9	Competing Mechanistic Hypotheses of Acetaminophen-Induced Hepatotoxicity Challenged by Virtual Experiments. PLoS Computational Biology, 2016, 12, e1005253.	3.2	22
10	Virtual Experiments Enable Exploring and Challenging Explanatory Mechanisms of Immune-Mediated P450 Down-Regulation. PLoS ONE, 2016, 11, e0155855.	2.5	14
11	In Silico, Experimental, Mechanistic Model for Extended-Release Felodipine Disposition Exhibiting Complex Absorption and a Highly Variable Food Interaction. PLoS ONE, 2014, 9, e108392.	2.5	6
12	Tuneable resolution as a systems biology approach for multiâ€scale, multiâ€compartment computational models. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2014, 6, 289-309.	6.6	53
13	Toward modular biological models: defining analog modules based on referent physiological mechanisms. BMC Systems Biology, 2014, 8, 95.	3.0	22
14	Agentâ€based modeling: a systematic assessment of use cases and requirements for enhancing pharmaceutical research and development productivity. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2013, 5, 461-480.	6.6	33
15	Synthetic Models and Methods. , 2013, , 2046-2050.		О
16	Individualized, discrete event, simulations provide insight into inter- and intra-subject variability of extended-release, drug products. Theoretical Biology and Medical Modelling, 2012, 9, 39.	2.1	6
17	Falsifying an Enzyme Induction Mechanism within a Validated, Multiscale Liver Model. International Journal of Agent Technologies and Systems, 2012, 4, 1-14.	0.1	5
18	Relational grounding facilitates development of scientifically useful multiscale models. Theoretical Biology and Medical Modelling, 2011, 8, 35.	2.1	24

#	Article	IF	CITATIONS
19	Moving beyond in silico tools to in silico science in support of drug development research. Drug Development Research, 2011, 72, 153-161.	2.9	8
20	Enabling Clearance Predictions to Emerge from In Silico Actions of Quasi-Autonomous Hepatocyte Components. Drug Metabolism and Disposition, 2011, 39, 1910-1920.	3.3	12
21	MDCK Cystogenesis Driven by Cell Stabilization within Computational Analogues. PLoS Computational Biology, 2011, 7, e1002030.	3.2	32
22	Advanced Concepts and Generative Simulation Formalisms for Creative Discovery Systems Engineering. Intelligent Systems Reference Library, 2011, , 233-258.	1.2	3
23	Cloud computing and validation of expandable in silico livers. BMC Systems Biology, 2010, 4, 168.	3.0	19
24	Computational experiments reveal plausible mechanisms for changing patterns of hepatic zonation of xenobiotic clearance and hepatotoxicity. Journal of Theoretical Biology, 2010, 265, 718-733.	1.7	17
25	Simulation of lung alveolar epithelial wound healing in vitro. Journal of the Royal Society Interface, 2010, 7, 1157-1170.	3.4	8
26	Tracing Multiscale Mechanisms of Drug Disposition in Normal and Diseased Livers. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 124-136.	2.5	29
27	Mechanistic Insight from In Silico Pharmacokinetic Experiments: Roles of P-glycoprotein, Cyp3A4 Enzymes, and Microenvironments. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 398-412.	2.5	22
28	Identifying the Rules of Engagement Enabling Leukocyte Rolling, Activation, and Adhesion. PLoS Computational Biology, 2010, 6, e1000681.	3.2	27
29	Agent-based simulation of drug disposition in cirrhotic liver. , 2010, , .		0
30	Simulating plausible mechanisms for changing hepatic xenobiotic clearance patterns. , 2010, , .		0
31	Agent-Directed Tracing of Multi-Scale Drug Disposition Events within Normal and Diseased In Silico Livers. International Journal of Agent Technologies and Systems, 2010, 2, 1-19.	0.1	4
32	A Computational Approach to Understand In Vitro Alveolar Morphogenesis. PLoS ONE, 2009, 4, e4819.	2.5	15
33	Computational Strategies Unravel and Trace How Liver Disease Changes Hepatic Drug Disposition. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 294-305.	2.5	24
34	Discovering Plausible Mechanistic Details of Hepatic Drug Interactions. Drug Metabolism and Disposition, 2009, 37, 237-246.	3.3	20
35	Evaluating an hepatic enzyme induction mechanism through coarse―and fineâ€grained measurements of an in silico liver. Complexity, 2009, 14, 28-34.	1.6	5
36	At the Biological Modeling and Simulation Frontier. Pharmaceutical Research, 2009, 26, 2369-2400.	3.5	73

#	Article	IF	Citations
37	Computational investigation of epithelial cell dynamic phenotype in vitro. Theoretical Biology and Medical Modelling, 2009, 6, 8.	2.1	17
38	A computational approach to resolve cell level contributions to early glandular epithelial cancer progression. BMC Systems Biology, 2009, 3, 122.	3.0	25
39	Modeling and Simulation of Hepatic Drug Disposition Using a Physiologically Based, Multi-agent In Silico Liver. Pharmaceutical Research, 2008, 25, 1023-1036.	3.5	46
40	New Simulation Methods to Facilitate Achieving a Mechanistic Understanding of Basic Pharmacology Principles in the Classroom. Journal of Science Education and Technology, 2008, 17, 366-372.	3.9	0
41	Dichotomies between computational and mathematical models. Nature Biotechnology, 2008, 26, 737-738.	17.5	36
42	Essential operating principles for tumor spheroid growth. BMC Systems Biology, 2008, 2, 110.	3.0	39
43	In Silico Methods for Unraveling the Mechanistic Complexities of Intestinal Absorption: Metabolism-Efflux Transport Interactions. Drug Metabolism and Disposition, 2008, 36, 1414-1424.	3.3	14
44	Predictions of Hepatic Disposition Properties Using a Mechanistically Realistic, Physiologically Based Model. Drug Metabolism and Disposition, 2008, 36, 759-768.	3.3	40
45	Mechanistic simulations explain paradoxical saquinavir metabolism during in vitro vectorial transport study., 2008, 2008, 5462-5.		3
46	In silico simulation of epithelial cell tubulogenesis. , 2008, 2008, 1036-9.		2
47	Using an In Silico Liver to evaluate a hepatic enzyme induction mechanism. , 2008, 2008, 2415-8.		2
48	A framework and mechanistically focused, in silico method for enabling rational translational research. Summit on Translational Bioinformatics, 2008, 2008, 46-50.	0.7	0
49	Formation of Cysts by Alveolar Type II Cells in Three-dimensional Culture Reveals a Novel Mechanism for Epithelial Morphogenesis. Molecular Biology of the Cell, 2007, 18, 1693-1700.	2.1	91
50	DEVS Peer-to-Peer Protocol for Distributed and Parallel Simulation of Hierarchical and Decomposable DEVS Models., 2007,,.		1
51	Dynamics of in silico leukocyte rolling, activation, and adhesion. BMC Systems Biology, 2007, 1, 14.	3.0	45
52	Challenges and rewards on the road to translational systems biology in acute illness: four case reports from interdisciplinary teams. Journal of Critical Care, 2007, 22, 169-175.	2.2	44
53	Simulation modeling of in vitro epithelial morphogenesis and malignancy. Journal of Critical Care, 2007, 22, 347-348.	2.2	0
54	An In Silico Transwell Device for the Study of Drug Transport and Drug–Drug Interactions. Pharmaceutical Research, 2007, 24, 2171-2186.	3.5	18

#	Article	IF	CITATIONS
55	Mechanistic Study of the Cellular Interplay of Transport and Metabolism Using the Synthetic Modeling Method. Pharmaceutical Research, 2006, 23, 493-505.	3.5	28
56	Physiologically Based Synthetic Models of Hepatic Disposition. Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33, 737-772.	1.8	58
57	Simulating Properties of In Vitro Epithelial Cell Morphogenesis. PLoS Computational Biology, 2006, 2, e129.	3.2	58
58	Prediction of in Vitro Hepatic Biliary Excretion using Stochastic Agent-Based Modeling and Fuzzy Clustering., 2006,,.		10
59	In Silico Analogues of Epithelial Cell Growth and Morphogenesis. , 2006, , .		0
60	Cost-based Partitioning for Distributed and Parallel Simulation of Decomposable Multiscale Constructive Models. Simulation, 2006, 82, 809-826.	1.8	3
61	An In Silico Analogue of In Vitro Systems Used to Study Epithelial Cell Morphogenesis. Lecture Notes in Computer Science, 2006, , 285-297.	1.3	2
62	Studies of intestinal drug transport using an in silico epithelio-mimetic device. BioSystems, 2005, 82, 154-167.	2.0	20
63	Biomimetic in Silico Devices. Lecture Notes in Computer Science, 2005, , 34-42.	1.3	2
64	Simulating Properties of In Vitro Epithelial Cell Morphogenesis. PLoS Computational Biology, 2005, preprint, e129.	3.2	0
65	Bootstrapping for pharmacokinetic models: visualization of predictive and parameter uncertainty. Pharmaceutical Research, 1998, 15, 690-697.	3.5	12
66	Synthesis of DNA Dumbbells: Chemical vs. Enzymatic Ligation of Self-Complementary Oligonucleotides. Nucleosides & Nucleotides, 1997, 16, 41-51.	0.5	12
67	Characterization of apocytochrome C binding to human erythrocytes. American Journal of Hematology, 1994, 47, 132-134.	4.1	0
68	Antisense c-myc oligodeoxyribonucleotide cellular uptake. Pharmaceutical Research, 1992, 09, 1010-1017.	3.5	59
69	Buffer effects on swelling kinetics in polybasic gels. Pharmaceutical Research, 1992, 09, 76-81.	3.5	40
70	Artificial Red Cells. A Link Between the Membrane Skeleton and Res Detectability?. Biomaterials, Artificial Cells, and Artificial Organs, 1990, 18, 329-343.	0.2	5
71	Some Unique Properties of a Bilayer and Liposome Forming System. Materials Research Society Symposia Proceedings, 1987, 110, 413.	0.1	O
72	Synthesis of Artificial Models of Sickle Red Cells. Materials Research Society Symposia Proceedings, 1987, 110, 99.	0.1	0

#	Article	IF	CITATION
73	Murine plasma fibronectin depletion after intravenous injection of liposomes. International Journal of Pharmaceutics, 1987, 37, 233-238.	5.2	11
74	Engineering targeted in vivo drug delivery. I. The physiological and physicochemical principles governing opportunities and limitations. Pharmaceutical Research, 1986, 03, 333-344.	3. 5	83
75	Lymphatic transport of liposome-encapsulated drugs following intraperitoneal administration - effect of lipid composition. Pharmaceutical Research, 1985, 02, 271-278.	3.5	40
76	LIGHT SENSITIVE LIPOSOMES. Photochemistry and Photobiology, 1983, 37, 491-494.	2.5	49
77	Liposome Dialysis for Improved Size Distributions. Journal of Pharmaceutical Sciences, 1982, 71, 806-812.	3.3	16
78	Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. Journal of Pharmacokinetics and Pharmacodynamics, 1981, 9, 245-260.	0.6	40